{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:48:36Z","timestamp":1762660116839,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jewish Heritage Fund for Excellence"},{"DOI":"10.13039\/100001010","name":"James Graham Brown Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Owsley Brown Family Foundation"},{"name":"Norton Healthcare"},{"name":"NIH","award":["R01      AG061065"],"award-info":[{"award-number":["R01      AG061065"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Serological assays intended for diagnosis, sero-epidemiologic assessment, and measurement of protective antibody titers upon infection or vaccination are essential for managing the SARS-CoV-2 pandemic. Serological assays measuring the antibody responses against SARS-CoV-2 antigens are readily available. However, some lack appropriate characteristics to accurately measure SARS-CoV-2 antibodies titers and neutralization. We developed an Enzyme-linked Immunosorbent Assay (ELISA) methods for measuring IgG, IgA, and IgM responses to SARS-CoV-2, Spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins. Performance characteristics of sensitivity and specificity have been defined. ELISA results show positive correlation with microneutralization and Plaque Reduction Neutralization assays with infectious SARS-CoV-2. Our ELISA was used to screen healthcare workers in Louisville, KY during the first wave of the local pandemic in the months of May and July 2020. We found a seropositive rate of approximately 1.4% and 2.3%, respectively. Our analyses demonstrate a broad immune response among individuals and suggest some non-RBD specific S IgG and IgA antibodies neutralize SARS-CoV-2.<\/jats:p>","DOI":"10.1038\/s41598-021-97423-z","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T10:03:16Z","timestamp":1631613796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky"],"prefix":"10.1038","volume":"11","author":[{"given":"Krystal T.","family":"Hamorsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne M.","family":"Bushau-Sprinkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Kitterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia M.","family":"Corman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"DeMarco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel J.","family":"Keith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruni","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua L.","family":"Fuqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Lasnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joongho","family":"Joh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marti","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirish","family":"Barve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita S.","family":"Ghare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"97423_CR1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3201\/eid2607.200841","volume":"26","author":"NMA Okba","year":"2020","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2\u2212specific antibody responses in coronavirus disease patients. Emerg. Infect. Dis. 26, 1478\u20131488. https:\/\/doi.org\/10.3201\/eid2607.200841 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"97423_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.30.20047365","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv https:\/\/doi.org\/10.1101\/2020.03.30.20047365 (2020).","journal-title":"medRxiv"},{"key":"97423_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3201\/eid1201.050979","volume":"12","author":"JK Taubenberger","year":"2006","unstructured":"Taubenberger, J. K. & Morens, D. M. 1918 Influenza: The mother of all pandemics. Emerg. Infect. Dis. 12, 15\u201322. https:\/\/doi.org\/10.3201\/eid1201.050979 (2006).","journal-title":"Emerg. Infect. Dis."},{"key":"97423_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.24.20042382","author":"W Tan","year":"2020","unstructured":"Tan, W. et al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv https:\/\/doi.org\/10.1101\/2020.03.24.20042382 (2020).","journal-title":"medRxiv"},{"key":"97423_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.18.20038059","author":"NMA Okba","year":"2020","unstructured":"Okba, N. M. A. et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv https:\/\/doi.org\/10.1101\/2020.03.18.20038059 (2020).","journal-title":"medRxiv"},{"key":"97423_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848. https:\/\/doi.org\/10.1038\/s41591-020-0897-1 (2020).","journal-title":"Nat. Med."},{"key":"97423_CR7","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 5, 1598\u20131607. https:\/\/doi.org\/10.1038\/s41564-020-00813-8 (2020).","journal-title":"Nat. Microbiol."},{"key":"97423_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4161\/mabs.2.1.10788","volume":"2","author":"JD Berry","year":"2010","unstructured":"Berry, J. D. et al. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs 2, 53\u201366. https:\/\/doi.org\/10.4161\/mabs.2.1.10788 (2010).","journal-title":"MAbs"},{"key":"97423_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-0913-5 (2020).","journal-title":"Nat. Med."},{"key":"97423_CR10","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1038\/s41598-017-06062-w","volume":"7","author":"Y Cong","year":"2017","unstructured":"Cong, Y., Kriegenburg, F., de Haan, C. A. M. & Reggiori, F. Coronavirus nucleocapsid proteins assemble constitutively in high molecular oligomers. Sci. Rep. 7, 5740. https:\/\/doi.org\/10.1038\/s41598-017-06062-w (2017).","journal-title":"Sci. Rep."},{"key":"97423_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbrc.2020.04.136","volume":"527","author":"W Zeng","year":"2020","unstructured":"Zeng, W. et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem. Biophys. Res. Commun. 527, 618\u2013623. https:\/\/doi.org\/10.1016\/j.bbrc.2020.04.136 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"97423_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bbrc.2005.08.032","volume":"336","author":"B Shang","year":"2005","unstructured":"Shang, B. et al. Characterization and application of monoclonal antibodies against N protein of SARS-coronavirus. Biochem. Biophys. Res. Commun. 336, 110\u2013117. https:\/\/doi.org\/10.1016\/j.bbrc.2005.08.032 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"97423_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/v12030254","volume":"12","author":"SF Ahmed","year":"2020","unstructured":"Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12, 254. https:\/\/doi.org\/10.3390\/v12030254 (2020).","journal-title":"Viruses"},{"key":"97423_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.13.20130252","author":"T Liu","year":"2020","unstructured":"Liu, T. et al. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan: Implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2. medRxiv https:\/\/doi.org\/10.1101\/2020.06.13.20130252 (2020).","journal-title":"medRxiv"},{"key":"97423_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104480","volume":"129","author":"N Kohmer","year":"2020","unstructured":"Kohmer, N., Westhaus, S., R\u00fchl, C., Ciesek, S. & Rabenau, H. F. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J. Clin. Virol. 129, 104480. https:\/\/doi.org\/10.1016\/j.jcv.2020.104480 (2020).","journal-title":"J. Clin. Virol."},{"key":"97423_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.21.20109280","author":"C Klumpp-Thomas","year":"2020","unstructured":"Klumpp-Thomas, C. et al. Standardization of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling. medRxiv https:\/\/doi.org\/10.1101\/2020.05.21.20109280 (2020).","journal-title":"medRxiv"},{"key":"97423_CR17","doi-asserted-by":"publisher","first-page":"e00461-00420","DOI":"10.1128\/JCM.00461-20","volume":"58","author":"W Liu","year":"2020","unstructured":"Liu, W. et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J. Clin. Microbiol. 58, e00461-00420. https:\/\/doi.org\/10.1128\/JCM.00461-20 (2020).","journal-title":"J. Clin. Microbiol."},{"key":"97423_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6952","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science https:\/\/doi.org\/10.1126\/science.abc6952 (2020).","journal-title":"Science"},{"key":"97423_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119. https:\/\/doi.org\/10.1038\/s41586-020-2380-z (2020).","journal-title":"Nature"},{"key":"97423_CR20","doi-asserted-by":"publisher","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","volume":"5","author":"L Premkumar","year":"2020","unstructured":"Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413. https:\/\/doi.org\/10.1126\/sciimmunol.abc8413 (2020).","journal-title":"Sci. Immunol."},{"key":"97423_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","volume":"26","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033\u20131036. https:\/\/doi.org\/10.1038\/s41591-020-0913-5 (2020).","journal-title":"Nat. Med."},{"key":"97423_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0949-6","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-0949-6 (2020).","journal-title":"Nat. Med."},{"key":"97423_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/infdis\/jiaa229","volume":"222","author":"G Zhang","year":"2020","unstructured":"Zhang, G., Nie, S., Zhang, Z. & Zhang, Z. Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019. J. Infect. Dis. 222, 183\u2013188. https:\/\/doi.org\/10.1093\/infdis\/jiaa229 (2020).","journal-title":"J. Infect. Dis."},{"key":"97423_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41423-020-0474-z","volume":"17","author":"H Ma","year":"2020","unstructured":"Ma, H. et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol. Immunol. 17, 773\u2013775. https:\/\/doi.org\/10.1038\/s41423-020-0474-z (2020).","journal-title":"Cell Mol. Immunol."},{"key":"97423_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa344","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa344 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"97423_CR26","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","volume":"181","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell 181, 1004\u20131015. https:\/\/doi.org\/10.1016\/j.cell.2020.04.031 (2020).","journal-title":"Cell"},{"key":"97423_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","volume":"17","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell. Mol. Immunol. 17, 647\u2013649. https:\/\/doi.org\/10.1038\/s41423-020-0426-7 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"97423_CR28","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274\u20131278. https:\/\/doi.org\/10.1126\/science.abc2241 (2020).","journal-title":"Science"},{"key":"97423_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent Neutralizing Antibodies Against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73\u201384. https:\/\/doi.org\/10.1016\/j.cell.2020.05.025 (2020).","journal-title":"Cell"},{"key":"97423_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.10.20126532","author":"D Sterlin","year":"2020","unstructured":"Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. medRxiv https:\/\/doi.org\/10.1101\/2020.06.10.20126532 (2020).","journal-title":"medRxiv"},{"key":"97423_CR31","doi-asserted-by":"publisher","first-page":"13463","DOI":"10.1073\/pnas.1410980111","volume":"111","author":"SR Bidgood","year":"2014","unstructured":"Bidgood, S. R., Tam, J. C. H., McEwan, W. A., Mallery, D. L. & James, L. C. Translocalized IgA mediates neutralization and stimulates innate immunity inside infected cells. Proc. Natl. Acad. Sci. U S A 111, 13463\u201313468. https:\/\/doi.org\/10.1073\/pnas.1410980111 (2014).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"97423_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085582","volume":"9","author":"M Muramatsu","year":"2014","unstructured":"Muramatsu, M. et al. Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: Increased potential of IgA for heterosubtypic immunity. PLoS ONE 9, e85582. https:\/\/doi.org\/10.1371\/journal.pone.0085582 (2014).","journal-title":"PLoS ONE"},{"key":"97423_CR33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/eji.1830140414","volume":"14","author":"FY Liew","year":"1984","unstructured":"Liew, F. Y., Russell, S. M., Appleyard, G., Brand, C. M. & Beale, J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur. J. Immunol. 14, 350\u2013356. https:\/\/doi.org\/10.1002\/eji.1830140414 (1984).","journal-title":"Eur. J. Immunol."},{"key":"97423_CR34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/jmv.20173","volume":"74","author":"Y Asahi-Ozaki","year":"2004","unstructured":"Asahi-Ozaki, Y. et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J. Med. Virol. 74, 328\u2013335. https:\/\/doi.org\/10.1002\/jmv.20173 (2004).","journal-title":"J. Med. Virol."},{"key":"97423_CR35","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.4161\/hv.25458","volume":"9","author":"A Ainai","year":"2013","unstructured":"Ainai, A. et al. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum. Vaccin. Immunother. 9, 1962\u20131970. https:\/\/doi.org\/10.4161\/hv.25458 (2013).","journal-title":"Hum. Vaccin. Immunother."},{"key":"97423_CR36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1099\/vir.0.81579-0","volume":"87","author":"RH See","year":"2006","unstructured":"See, R. H. et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol. 87, 641\u2013650. https:\/\/doi.org\/10.1099\/vir.0.81579-0 (2006).","journal-title":"J. Gen. Virol."},{"key":"97423_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220196","volume":"14","author":"MH Kim","year":"2019","unstructured":"Kim, M. H., Kim, H. J. & Chang, J. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus. PLoS ONE 14, e0220196. https:\/\/doi.org\/10.1371\/journal.pone.0220196 (2019).","journal-title":"PLoS ONE"},{"key":"97423_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184. https:\/\/doi.org\/10.1016\/j.cell.2020.08.026 (2020).","journal-title":"Cell"},{"key":"97423_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215414","author":"A Shields","year":"2020","unstructured":"Shields, A. et al. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: A cross-sectional study. Thorax https:\/\/doi.org\/10.1136\/thoraxjnl-2020-215414 (2020).","journal-title":"Thorax"},{"key":"97423_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jhin.2020.06.028","volume":"106","author":"C Martin","year":"2020","unstructured":"Martin, C. et al. Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff. J. Hosp. Infect. 106, 102\u2013106. https:\/\/doi.org\/10.1016\/j.jhin.2020.06.028 (2020).","journal-title":"J. Hosp. Infect."},{"key":"97423_CR41","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.15585\/mmwr.mm6935e2","volume":"69","author":"WH Self","year":"2020","unstructured":"Self, W. H. et al. Seroprevalence of SARS-CoV-2 among frontline health care personnel in a multistate hospital network\u201413 Academic Medical Centers, April-June 2020. MMWR Morb. Mortal. Wkly Rep. 69, 1221\u20131226. https:\/\/doi.org\/10.15585\/mmwr.mm6935e2 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"97423_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmaa078","author":"K Lackermair","year":"2020","unstructured":"Lackermair, K. et al. Infection with SARS-CoV-2 in primary care health care workers assessed by antibody testing. Fam. Pract. https:\/\/doi.org\/10.1093\/fampra\/cmaa078 (2020).","journal-title":"Fam. Pract."},{"key":"97423_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.07.033","author":"L Blairon","year":"2020","unstructured":"Blairon, L. et al. Large-scale, molecular and serological SARS-CoV-2 screening of healthcare workers in a 4-site public hospital in Belgium after COVID-19 outbreak. J. Infect. https:\/\/doi.org\/10.1016\/j.jinf.2020.07.033 (2020).","journal-title":"J. Infect."},{"key":"97423_CR44","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1017\/ice.2020.401","volume":"41","author":"A Amendola","year":"2020","unstructured":"Amendola, A. et al. Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave. Infect. Control Hosp. Epidemiol. 41, 1468\u20131469. https:\/\/doi.org\/10.1017\/ice.2020.401 (2020).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"97423_CR45","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jama.2020.14765","volume":"324","author":"J Moscola","year":"2020","unstructured":"Moscola, J. et al. Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York City area. JAMA 324, 893\u2013895. https:\/\/doi.org\/10.1001\/jama.2020.14765 (2020).","journal-title":"JAMA"},{"key":"97423_CR46","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.4214","author":"A Jeremias","year":"2020","unstructured":"Jeremias, A. et al. Prevalence of SARS-CoV-2 infection among health care workers in a Tertiary Community Hospital. JAMA Intern. Med. https:\/\/doi.org\/10.1001\/jamainternmed.2020.4214 (2020).","journal-title":"JAMA Intern. Med."},{"key":"97423_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12890-020-01237-0","volume":"20","author":"G Sotgiu","year":"2020","unstructured":"Sotgiu, G. et al. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital. BMC Pulm. Med. 20, 203. https:\/\/doi.org\/10.1186\/s12890-020-01237-0 (2020).","journal-title":"BMC Pulm. Med."},{"key":"97423_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1017\/ice.2020.402","volume":"42","author":"JJ Grant","year":"2020","unstructured":"Grant, J. J. et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust. Infect. Control Hosp. Epidemiol. 42, 212\u2013214. https:\/\/doi.org\/10.1017\/ice.2020.402 (2020).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"97423_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104437","volume":"128","author":"J Korth","year":"2020","unstructured":"Korth, J. et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J. Clin. Virol. 128, 104437. https:\/\/doi.org\/10.1016\/j.jcv.2020.104437 (2020).","journal-title":"J. Clin. Virol."},{"key":"97423_CR50","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1038\/s41467-020-17318-x","volume":"11","author":"AL Garcia-Basteiro","year":"2020","unstructured":"Garcia-Basteiro, A. L. et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat. Commun. 11, 3500. https:\/\/doi.org\/10.1038\/s41467-020-17318-x (2020).","journal-title":"Nat. Commun."},{"key":"97423_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa936","author":"WB Stubblefield","year":"2020","unstructured":"Stubblefield, W. B. et al. Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for COVID-19 patients\u2014Nashville, Tennessee. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa936 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"97423_CR52","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ijid.2020.09.1484","volume":"101","author":"T Shirin","year":"2020","unstructured":"Shirin, T. et al. Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh. Int. J. Infect. Dis. 101, 220\u2013225. https:\/\/doi.org\/10.1016\/j.ijid.2020.09.1484 (2020).","journal-title":"Int. J. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97423-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97423-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97423-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:24:43Z","timestamp":1670081083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97423-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97423"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97423-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"16 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18285"}}